Glonghui, Feb. 28 | Bank of America Securities released a report saying that BeiGene's total revenue and product revenue last year were US$2,459 million and US$2.19 billion respectively, up 73.7% and 74.5% year-on-year, mainly benefiting from the strong growth of the drug Brukinsa in the global market. Revenue growth is roughly in line with the bank's forecast of 72.1% year-on-year growth. According to Bank of America Securities, considering the strong sales and pipeline progress of BeiGene products in the global market, it raised the POS and sales expectations for Brukinsa and Tislelizumab starting this year, and included Sonrotoclax's revenue expectations. At the same time, the forecast for R&D and marketing expenses from 2024 to 2026 was raised. Therefore, in view of the company's ability to maintain a good business development trend under fierce competition and price reduction pressure in the Chinese market, the target price was raised from HK$98.43 to HK$103.5, reaffirming the “neutral” rating, indicating that the company has established a leading position in global hematology.